Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  1,752 results for ""RITUXIMAB""

Your Filters

Geographic : japan
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.

  • Authors : Yamauchi N; Department of Hematology, National Cancer Center East Hospital, Kashiwa, Japan.; Maruyama D

Subjects: Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/*therapeutic use ; Antiviral Agents/Antiviral Agents/Antiviral Agents/*therapeutic use ; Hepatitis B/Hepatitis B/Hepatitis B/*drug therapy

  • Source: Cancer science [Cancer Sci] 2021 May; Vol. 112 (5), pp. 1943-1954. Date of Electronic Publication: 2021 Mar 18.Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic

Record details

Read More Add to Saved list
×
Academic Journal

A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.

  • Authors : Izutsu K; Department of Hematology, Toranomon Hospital, Tokyo, Japan.; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Cyclophosphamide/Cyclophosphamide/Cyclophosphamide/*therapeutic use ; Leukemia, Lymphocytic, Chronic, B-Cell/Leukemia, Lymphocytic, Chronic, B-Cell/Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy

  • Source: Japanese journal of clinical oncology [Jpn J Clin Oncol] 2021 Mar 03; Vol. 51 (3), pp. 408-415.Publisher: Oxford University Press Country of Publication: England NLM ID: 0313225 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma.

  • Authors : Kusumoto S; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.; Tanaka Y

Subjects: Hepatitis B Surface Antigens*/Hepatitis B Surface Antigens*/Hepatitis B Surface Antigens*/analysis ; Hepatitis B Surface Antigens*/Hepatitis B Surface Antigens*/Hepatitis B Surface Antigens*/blood ; Hepatitis B virus*/Hepatitis B virus*/Hepatitis B virus*/drug effects

  • Source: Journal of hepatology [J Hepatol] 2020 Aug; Vol. 73 (2), pp. 285-293. Date of Electronic Publication: 2020 Mar 17.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8503886 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).

  • Authors : Nagano C; Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.; Sako M

Subjects: Randomized Controlled Trials as Topic*; Immunologic Factors/Immunologic Factors/Immunologic Factors/*therapeutic use ; Nephrotic Syndrome/Nephrotic Syndrome/Nephrotic Syndrome/*drug therapy

  • Source: BMC nephrology [BMC Nephrol] 2019 Aug 02; Vol. 20 (1), pp. 293. Date of Electronic Publication: 2019 Aug 02.Publisher: BioMed Central Country of Publication: England NLM ID: 100967793 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2369

Record details

Read More Add to Saved list
×
Academic Journal

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.

  • Authors : Tahara M; Clinical Research Centre and Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto, Japan. Electronic address: .; Oeda T

Subjects: Aquaporin 4/Aquaporin 4/Aquaporin 4/*genetics ; Immunologic Factors/Immunologic Factors/Immunologic Factors/*therapeutic use ; Neuromyelitis Optica/Neuromyelitis Optica/Neuromyelitis Optica/*drug therapy

  • Source: The Lancet. Neurology [Lancet Neurol] 2020 Apr; Vol. 19 (4), pp. 298-306. Date of Electronic Publication: 2020 Mar 18.Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 101139309 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan.

  • Authors : Kubo M; Department of Blood Transfusion Medicine, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.; Sakai K

Subjects: Off-Label Use*; Purpura, Thrombocytopenic, Idiopathic/Purpura, Thrombocytopenic, Idiopathic/Purpura, Thrombocytopenic, Idiopathic/*drug therapy ; Rituximab/Rituximab/Rituximab/*therapeutic use

  • Source: International journal of hematology [Int J Hematol] 2020 Dec; Vol. 112 (6), pp. 764-772. Date of Electronic Publication: 2020 Aug 27.Publisher: Springer Japan Country of Publication: Japan NLM ID: 9111627 Publication Model:

Record details

Read More Add to Saved list
×
Academic Journal

Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome.

  • Authors : Fujinaga S; Division of Nephrology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-ku, Saitama city, Saitama, 330-8777, Japan. .; Nishino T

Subjects: Immunosuppressive Agents/Immunosuppressive Agents/Immunosuppressive Agents/*therapeutic use ; Lymphocyte Depletion/Lymphocyte Depletion/Lymphocyte Depletion/*methods ; Nephrotic Syndrome/Nephrotic Syndrome/Nephrotic Syndrome/*drug therapy

  • Source: Pediatric nephrology (Berlin, Germany) [Pediatr Nephrol] 2019 Feb; Vol. 34 (2), pp. 353-357. Date of Electronic Publication: 2018 Nov 13.Publisher: Springer International Country of Publication: Germany NLM ID: 8708728 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Low incidence of posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab.

Subjects: Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/*therapeutic use ; Hematopoietic Stem Cell Transplantation/Hematopoietic Stem Cell Transplantation/Hematopoietic Stem Cell Transplantation/*methods ; Lymphoma, B-Cell/Lymphoma, B-Cell/Lymphoma, B-Cell/*therapy

  • Source: Hematological oncology [Hematol Oncol] 2020 Apr; Vol. 38 (2), pp. 146-152. Date of Electronic Publication: 2020 Feb 03.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation.

  • Authors : Maenosono R; Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.; Department of Urology, Osaka Medical College, Osaka, Japan.

Subjects: Blood Group Incompatibility/Blood Group Incompatibility/Blood Group Incompatibility/*therapy ; Graft Rejection/Graft Rejection/Graft Rejection/*epidemiology ; Immunosuppressive Agents/Immunosuppressive Agents/Immunosuppressive Agents/*therapeutic use

  • Source: International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2019 Dec; Vol. 26 (12), pp. 1114-1120. Date of Electronic Publication: 2019 Publisher: Blackwell Science Asia Country of Publication: Australia NLM ID: 9440237 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.

  • Authors : Ebata S; Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.; Yoshizaki A

Subjects: Cyclophosphamide/Cyclophosphamide/Cyclophosphamide/*therapeutic use ; Immunosuppressive Agents/Immunosuppressive Agents/Immunosuppressive Agents/*therapeutic use ; Lung Diseases, Interstitial/Lung Diseases, Interstitial/Lung Diseases, Interstitial/*drug therapy

  • Source: The Journal of dermatology [J Dermatol] 2019 Nov; Vol. 46 (11), pp. 1006-1013. Date of Electronic Publication: 2019 Sep 09.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7600545 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  1,752 results for ""RITUXIMAB""